Candel Therapeutics Plans Major Stock Offering
Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), located in Needham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative multimodal biological immunotherapies designed to support patients battling cancer. In a recent announcement, the company revealed its intent to initiate an underwritten public offering worth $80 million, primarily involving common stock. For specific investors, pre-funded warrants will also be made available as an alternative to common stock. Candel aims to offer all shares directly, and additionally, will provide underwriters with a 30-day option to acquire an extra $12 million in shares under similar terms and conditions. The offering’s completion is reliant on market conditions, and it's important to note that there’s no guarantee regarding the timeframe, size, or specific terms of the offering.
Usage of Proceeds for Cancer Development
The proceeds from this public offering are earmarked for advancing the development of Candel's pipeline, particularly for the Biologics License Application submission concerning the investigational product CAN-2409, which is focused on treating prostate cancer. The funds will also be utilized for various corporate purposes, ensuring the company can continue its mission effectively in a competitive environment.
Leadership in the Offering
Citigroup, BofA Securities, and Canaccord Genuity will serve as the joint bookrunning managers for this significant offering. H.C. Wainwright & Co. has been appointed as the lead manager, emphasizing Candel’s commitment to leveraging established financial institutions to support its ambitious goals.
Regulatory Framework and Transparency
A shelf registration statement on Form S-3 that includes the shares intended for this public offering had previously been filed with the Securities and Exchange Commission (SEC) and received effective status in August 2022. The public offering will strictly adhere to the specifics outlined in the registration statement, with necessary prospectuses being made available through SEC channels once filed. Interested parties will also have an option to acquire copies of the preliminary prospectus supplement as it becomes available through designated contacts.
About Candel Therapeutics and Its Innovations
Candel is paving the way in clinical biopharmaceutical innovation, concentrating on creating readily available biological immunotherapies tailored to generate robust anti-tumor immune responses. Their flagship product, CAN-2409, stems from a unique adenovirus platform currently advancing through several ongoing clinical trials targeting non-small cell lung cancer and pancreatic ductal adenocarcinoma. Additionally, CAN-3110, which represents the herpes simplex virus-based platform, is progressing through its phase 1b clinical trial aimed at recurrent high-grade glioma. The company’s enLIGHTEN™ Discovery Platform further enhances its research methodology, focusing on developing new viral immunotherapies for solid tumors while utilizing cutting-edge analytics and human biology.
Frequently Asked Questions
What is the primary purpose of Candel's $80 million offering?
The funds will be primarily used to advance the development of Candel's product candidates including CAN-2409 for prostate cancer.
Who manages the public offering for Candel Therapeutics?
Citigroup, BofA Securities, and Canaccord Genuity are the joint bookrunning managers, with H.C. Wainwright & Co. serving as the lead manager.
How much additional stock can underwriters purchase?
Underwriters have an option to purchase up to an additional $12 million in shares.
What is CAN-2409?
CAN-2409 is Candel’s lead product candidate that targets prostate cancer and is currently undergoing various clinical trials.
What types of therapies does Candel focus on developing?
Candel specializes in creating multimodal biological immunotherapies intended to enhance the immune response against cancer.
